Premium
Cibenzoline for High‐Frequency Ventricular Arrhythmias: A Short‐Term Comparison With Quinidine and a Long‐Term Follow‐up
Author(s) -
Palakurthy Prasad R.,
Maldonado Claudio,
Sohi Gurbachan,
Flowers Nancy C.
Publication year - 1987
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1987.tb03014.x
Subject(s) - quinidine , medicine , ventricular tachycardia , qrs complex , cardiology , qt interval , sustained ventricular tachycardia , antiarrhythmic agent , tachycardia , anesthesia , heart disease
Cibenzoline, a new class I antiarrhythmic drug, was compared with quinidine in an open crossover study of 20 patients with frequent (> 30/hr) premature ventricular depolarizations (PVDs). Eight patients treated with cibenzoline experienced more than 75% reduction in PVD frequency. Cibenzoline completely suppressed ventricular couplets in eight of 17 patients and inhibited ventricular tachycardia (VT) in four of 13 patients. Only four patients (20%) responded to quinidine with a similar reduction in PVDs. Quinidine completely suppressed ventricular couplets in eight of 17 patients and episodes of VT in six of 13 patients. Cibenzoline prolonged PR, QRS, and QT c intervals. Eight patients who had shown more than a 75% reduction of PVDs were treated with cibenzoline for an extended period. At the end of three months, only five of eight patients continued to have 75% or greater reduction of PVDs. At the end of six and 12 months, four of five patients continued to have 75% or greater reduction of PVDs. Cibenzoline was similarly effective in suppressing complex arrhythmias. Thus, cibenzoline was only slightly superior to quinidine in suppressing ventricular arrhythmias. With long‐term use of cibenzoline, significant PVD suppression was noted at the end of three months but not afterward.